Microcap Ledger GeoVax Labs, Inc. $GOVX
Facts as of . Built from SEC filings and our own data. Small caps move fast; check the latest filings.
Snapshot
- Exchange
- Nasdaq Capital Market
- Sector
- Pharmaceutical Preparations
- Headquarters
- Smyrna, GA
- Fiscal year end
- December 31
- Shares outstanding
- 7,369,243 [10-Q 2026-07-27]
What the company doesAI summary of filing
GeoVax Labs is a clinical-stage biotechnology company developing vaccines and immunotherapies using proprietary MVA-based platforms. The company's primary near-term focus is GEO-MVA, a Modified Vaccinia Ankara vaccine candidate for mpox and smallpox, advancing toward a Phase 3 trial planned for late 2026 on an expedited European regulatory pathway. The company also develops Gedeptin, an oncolytic gene therapy for solid tumors that completed Phase 1/2 trials and is planned for Phase 2 testing in combination with immune checkpoint inhibitors in early 2027, and GEO-CM04S1, a multi-antigen COVID-19 vaccine in Phase 2 trials for immunocompromised patients and as a booster vaccine. GeoVax is pre-revenue and funds operations through research and development activities supported by government partnerships and grants. [10-K 2026-04-15]
Financial health
| Period | Revenue | Net income | Operating cash flow | Cash | Filing |
|---|---|---|---|---|---|
| 6 months to Jun 2026 | $0.00 | −$9.69M | −$7.20M | $3.14M | [S-1 2026-09-17] |
| FY ended Dec 2025 | $2.49M | −$21.46M | −$21.47M | $3.09M | [S-1 2026-09-17] |
| FY ended Dec 2024 | $3.95M | −$24.99M | −$24.68M | $5.51M | [S-1 2026-09-17] |
- Quarterly cash burn
- −$3.60M
- Cash runway Estimate
- ~2.6 months
Capital structure and dilution
| Date | Shares outstanding | Filing |
|---|---|---|
| 2024-11-12 | 9,436,069 | [10-Q 2024-11-12] |
| 2025-03-27 | 13,839,478 | [10-K 2025-03-27] |
| 2025-04-30 | 15,193,593 | [10-Q 2025-05-01] |
| 2025-07-28 | 25,359,593 | [10-Q 2025-07-28] |
| 2025-11-13 | 29,705,360 | [10-Q 2025-11-13] |
| 2026-04-15 | 2,892,570 | [10-K 2026-04-15] |
| 2026-05-14 | 3,473,260 | [10-Q 2026-05-14] |
| 2026-07-27 | 7,369,243 | [10-Q 2026-07-27] |
- Shelf registration
- S-1 filed 2026-09-17; declared effective 2026-09-23 [S-1 2026-09-17]
Listing status
Current status: 4 Form 8-K Item 3.01 filing(s) in the last 24 months, most recent 2026-08-28. Item 3.01 covers delisting notices, failures to meet a listing rule and listing transfers; read the filing for which one.
| Date | Event | Details | Deadline | Filing |
|---|---|---|---|---|
| 2026-08-28 | 8-K Item 3.01 | Notice of delisting or failure to satisfy a continued listing rule or standard; or transfer of listing | — | [8-K 2026-08-28] |
| 2026-07-10 | 8-K Item 3.01 | Notice of delisting or failure to satisfy a continued listing rule or standard; or transfer of listing | — | [8-K 2026-07-10] |
| 2025-08-01 | 8-K Item 3.01 | Notice of delisting or failure to satisfy a continued listing rule or standard; or transfer of listing | — | [8-K 2025-08-01] |
| 2024-11-18 | 8-K Item 3.01 | Notice of delisting or failure to satisfy a continued listing rule or standard; or transfer of listing | — | [8-K 2024-11-18] |
Catalysts and calendar
| Date | Type | Title |
|---|---|---|
| 2026-09-17 | S-1 | Registration statement |
| 2026-09-10 | DEF 14A | Proxy statement |
| 2026-09-10 | 8-K | Other events |
| 2026-08-31 | PRE 14A | Proxy statement |
| 2026-08-28 | 8-K | Listing notice or transfer |
| 2026-08-28 | 8-K | Material agreement entered; Unregistered sale of equity |
| 2026-08-14 | 13G/A | Beneficial ownership report (5%+ holder) |
| 2026-08-13 | 13G/A | Beneficial ownership report (5%+ holder) |
| 2026-08-13 | 13G/A | Beneficial ownership report (5%+ holder) |
| 2026-08-10 | 13G/A | Beneficial ownership report (5%+ holder) |
| 2026-07-27 | 10-Q | Quarterly report |
| 2026-07-27 | 8-K | Results of operations |
Alerts for $GOVX
Email me when GeoVax Labs, Inc. files an offering, gets a deficiency notice, or moves sharply.
Facts as of . Small caps move fast; check the latest filings.